Lucid Diagnostics Inc. Common Stock (LUCD)

Price$0.97

Value ScoreF

Growth ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-16.68%

Price vs S&P 500 (4W)-6.09%

VGM Score43.01

Market Capitalization$196.41M

All Metrics

Book Value / Share (Quarterly)$0.02

P/TBV (Annual)13.45x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)131.36%

Cash Flow / Share (Quarterly)$-0.28

Price vs S&P 500 (YTD)-19.42%

Gross Margin (TTM)-31.38%

Net Profit Margin (TTM)-876.72%

EPS (TTM)$-0.36

10-Day Avg Trading Volume0.92M

EPS Excl Extra (TTM)$-0.36

EPS (Annual)$-0.57

ROI (Annual)-166.05%

Gross Margin (Annual)-41.73%

Net Profit Margin (5Y Avg)-4969.40%

Cash / Share (Quarterly)$0.17

Revenue Growth QoQ (YoY)51.69%

ROA (Last FY)-143.43%

Revenue Growth TTM (YoY)23.03%

EBITD / Share (TTM)$-0.42

Operating Margin (TTM)-980.64%

Cash Flow / Share (Annual)$-0.36

P/B Ratio49.10x

P/B Ratio (Quarterly)50.87x

Net Income / Employee (Annual)$-707,400

EV / Revenue (TTM)37.73x

Net Interest Coverage (TTM)-41.55x

ROA (TTM)-108.20%

EPS Incl Extra (Annual)$-0.57

Current Ratio (Annual)1.31x

Quick Ratio (Quarterly)1.02x

3-Month Avg Trading Volume0.82M

52-Week Price Return-20.07%

Revenue / Employee (TTM)$62,600

Tangible BV / Share (Quarterly)$0.02

P/S Ratio (Annual)41.74x

Asset Turnover (Annual)0.12x

52-Week High$1.63

Operating Margin (5Y Avg)-4903.94%

EPS Excl Extra (Annual)$-0.57

26-Week Price Return-8.75%

Quick Ratio (Annual)1.27x

13-Week Price Return-30.91%

Total Debt / Equity (Annual)2.19x

Current Ratio (Quarterly)1.07x

Enterprise Value$193.73M

Asset Turnover (TTM)0.12x

Revenue / Employee (Annual)$57,400

Pretax Margin (Annual)-1232.68%

Cash / Share (Annual)$0.26

3-Month Return Std Dev62.69%

Gross Margin (5Y Avg)-224.39%

Net Income / Employee (TTM)$-548,900

ROE (Last FY)-530.45%

Net Interest Coverage (Annual)-212.25x

EPS Basic Excl Extra (Annual)$-0.57

Receivables Turnover (TTM)13.69x

Total Debt / Equity (Quarterly)6.30x

EPS Incl Extra (TTM)$-0.36

Receivables Turnover (Annual)13.68x

ROI (TTM)-123.80%

P/S Ratio (TTM)38.26x

Pretax Margin (5Y Avg)-4969.40%

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$0.08

Price vs S&P 500 (52W)-44.43%

Year-to-Date Return-11.27%

5-Day Price Return-6.10%

EPS Normalized (Annual)$-0.57

ROA (5Y Avg)-141.03%

Net Profit Margin (Annual)-1232.68%

Month-to-Date Return-6.10%

Cash Flow / Share (TTM)$-1.34

EBITD / Share (Annual)$-0.49

Operating Margin (Annual)-1077.73%

EPS Basic Excl Extra (TTM)$-0.36

P/TBV (Quarterly)53.69x

P/B Ratio (Annual)13.07x

Inventory Turnover (TTM)14.16x

Pretax Margin (TTM)-876.72%

Book Value / Share (Annual)$0.08

Price vs S&P 500 (13W)-39.17%

Beta1.15x

Revenue / Share (TTM)$0.04

ROE (TTM)-370.21%

52-Week Low$0.90

vGradeF

gGradeA

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.17est. -0.08

Q1 26-0.07est. -0.08

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.17

4.18

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
LUCDLucid Diagnostics Inc. Common Stock	F	A	D	$0.97
SYKStryker Corporation	C	C	C	$305.66
MMM3M Company	C	F	C	$153.76
BSXBoston Scientific Corp.	C	B	D	$48.55
MDLNMedline Inc. Class A common stock	C	D	D	$33.61
BDXBecton, Dickinson and Co.	B	C	C	$151.16
RMDResMed Inc.	C	B	C	$196.04
DXCMDexCom, Inc.	C	B	C	$72.86
WSTWest Pharmaceutical Services, Inc.	D	C	B	$314.50
SOLVSolventum Corporation	C	D	B	$81.01
PENPenumbra, Inc.	F	C	B	$320.53

About

Lucid Diagnostics is a commercial-stage company developing diagnostic tools for patients with gastroesophageal reflux disease (GERD) at risk of esophageal cancer. Its products, EsoCheck and EsoGuard, enable detection of precancerous changes in the esophagus, addressing an unmet clinical need in cancer prevention. The company targets a significant market opportunity among millions of GERD patients vulnerable to esophageal adenocarcinoma.